Skip to main content

Home/ Dr. Goodyear/ Group items tagged doxorubicin

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer t... - 0 views

www.sciencedirect.com/...S0960977617300103

HER-2 breast cancer cancer herceptin Perjeta

shared by Nathan Goodyear on 06 Aug 18 - No Cached
  • 15%–20%
  • key mediator of cell growth, differentiation, and survival
  • of higher histological grade and are more likely to invade axillary lymph nodes
  • ...15 more annotations...
  • shortened survival and an increased risk of disease recurrence and metastasis
  • Currently, four HER2-directed agents are approved for the treatment of patients with HER2+ breast cancer: trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1)
  • biosimilars
  • trastuzumab may provide greater benefit when administered concurrently with chemotherapy rather than after, and this has become the standard approach
  • concurrent use of anthracyclines (ie, doxorubicin or epirubicin) and trastuzumab is not recommended because of an increased risk for cardiac toxicity
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      avoid herceptin in conjuction with antracyclines i.e. doxorubicin
  • Sequential doxorubicin plus cyclophosphamide followed by concomitant paclitaxel or docetaxel and trastuzumab is recommended for most patients
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      top recommended regimen combination
  • Guidelines also recommend trastuzumab in combination with paclitaxel, docetaxel and carboplatin, or docetaxel and cyclophosphamide, particularly for patients with increased risk for cardiac toxicity or those with small (≤1 cm), node-negative HER2+ tumors
    • Nathan Goodyear
      Nathan Goodyear on 06 Aug 18
       
      good alternative in patients with increased risk of cardiac toxicity.
  • guidelines recommend up to 1 year of adjuvant trastuzumab
  • Neoadjuvant chemotherapy with trastuzumab is associated with higher rates of pathologic complete response (pCR) than chemotherapy alone or in combination with lapatinib
  • the combination of trastuzumab, lapatinib, and chemotherapy is not recommended because it failed to demonstrate noninferiority versus trastuzumab and chemotherapy in the adjuvant setting
  • recommend the combination of trastuzumab, pertuzumab, and chemotherapy as neoadjuvant treatment for patients with locally advanced HER2+ breast cancer and for some patients (node-positive or tumor ≥2 cm) with early-stage disease
  • neoadjuvant chemotherapy in combination with pertuzumab and trastuzumab reduced the risk of progression or death by 31% and recurrence or death by 40% versus trastuzumab alone
  • Concurrent chemotherapy and HER2-directed therapy improves survival outcomes over chemotherapy alon
  • dual inhibition of HER2 with trastuzumab and pertuzumab in combination with paclitaxel reduced the risk of death or progression by approximately 40% compared with concurrent trastuzumab and paclitaxel
  • the combination of trastuzumab, pertuzumab, and taxane chemotherapy is the preferred first-line regimen
  • Nathan Goodyear on 06 Aug 18
     
    HER-2 + breast cancer = appx 15-20% of all breast cancers and is a marker of worse prognosis and an indication for targeted immunotherapy blockade.
Nathan Goodyear

Chemotherapy-Induced Late Transgenerational Effects in Mice | PLOS ONE - 0 views

journals.plos.org/...article

transgenerational inheritance chemotherapy doxorubicin

shared by Nathan Goodyear on 19 Dec 22 - No Cached
  • Nathan Goodyear on 19 Dec 22
     
    Animal model finds doxorubicin chemotherapy induces epigenetic transgenerational inheritence
Nathan Goodyear

Effects of Angiotensin, Vasopressin and Aldosterone on Proliferation of MCF-7 Cells and... - 0 views

ar.iiarjournals.org/...1843.full

cancer breast cancer renin angiotensin system aldosterone

shared by Nathan Goodyear on 10 Sep 18 - No Cached
  • The renin-angiotensin system (RAS) has been associated with local tumor growth, inflammation, angiogenesis and facilitation of metastasis
  • Aldosterone and vasopressin did not alter cellular growth (Figure 1) and did not alter doxorubicin sensitivity
  • angiotensin increased the growth of MCF-7 cells
  • ...2 more annotations...
  • losartan
  • evidence that breast cancer chemotherapy can be influenced by anti-hypertensive treatment
  • Nathan Goodyear on 10 Sep 18
     
    upregulated RAS associated with stimulated breast cancer growth.  Anti-hypertensive therapy not only can it impact the cancer growth potential but also can augment chemotherapy.
Nathan Goodyear

Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apop... - 0 views

pubmed.ncbi.nlm.nih.gov/24908637

triple negative breast cancer Boswellia TNBC chemotherapy

shared by Nathan Goodyear on 30 Apr 21 - No Cached
  • Nathan Goodyear on 30 Apr 21
     
    Boswellia shows chemosensitizing effects with doxorubicin and cisplatin with TNBC.
Nathan Goodyear

Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer - ScienceD... - 0 views

www.sciencedirect.com/...S0936655509000314

platinum breast cancer BRCA

shared by Nathan Goodyear on 14 May 21 - No Cached
  • Nathan Goodyear on 14 May 21
     
    BRCA indicates increased platinum sensitivity and decreased doxorubicin sensitivity.
Nathan Goodyear

Concomitant low-dose doxorubicin treatment and exercise | Regulatory, Integrative and C... - 0 views

ajpregu.physiology.org/...R685

exercise cancer

shared by Nathan Goodyear on 23 Sep 14 - No Cached
  • Nathan Goodyear on 23 Sep 14
     
    Study finds exercise useful as adjuvant to chemotherapy in the treatment of cancer.  The exercise consisted of 45 mins/day for 5 days. 
Nathan Goodyear

Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound d... - 0 views

www.tandfonline.com/...1061186X.2011.622403

Bemer cancer chemotherapy lymphoma

shared by Nathan Goodyear on 19 Nov 18 - No Cached
  • Nathan Goodyear on 19 Nov 18
     
    Bemer found to be synergistic with chemotherapy in mouse model lymphoma.
Nathan Goodyear

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblasti... - 0 views

ascopubs.org/...JCO.2018.79.0139

Hodgkin's lymphoma Hodgkin's disease lymphoma immunotherapy cancer chemotherapy monoclonal antibodies

shared by Nathan Goodyear on 13 Sep 18 - No Cached
  • Nathan Goodyear on 13 Sep 18
     
    monoclonal Ab used in sequence with AVD found to have event-free survival, progression-free survival, and overal survival rates of 80%, 84%, and 93% respectively in older adults with Hodgkin's lymphoma.
Nathan Goodyear

Transarterial Chemoembolization With Doxorubicin-Eluting Microspheres for Inoperable He... - 0 views

www.ncbi.nlm.nih.gov/...PMC3070282

TACE DEB-TACE liver liver cancer cancer

shared by Nathan Goodyear on 26 Jul 18 - No Cached
  • Nathan Goodyear on 26 Jul 18
     
    Transarterial chemoembolization with micropheres called DEB-TACE for liver tumors.
Nathan Goodyear

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on g... - 0 views

www.ncbi.nlm.nih.gov/...PMC4741919

adenoid cystic carcinoma

shared by Nathan Goodyear on 03 Oct 18 - No Cached
  • Cisplatin and 5-FU or CAP (cisplatin, doxorubicin, and cyclophosphamide) regimens can be used for combination chemotherapy
  • patients with advanced salivary gland malignancy treated with the CAP regimen achieved partial response (PR) or stable disease (SD) rates of 67% (8 out of 12 patients)
  • Agents commonly given as monotherapy for treating ACC are cisplatin, mitoxantrone, epirubicin, vinorelbine, paclitaxel, and gemcitabine. However, few of these agents have shown efficacy
  • ...23 more annotations...
  • single agent mitoxantrone or vinorelbine were recommended as reasonable choices
  • ACC is subdivided into 3 histological groups based on solid components of the tumor including cribriform, tubular, and solid
  • Cribriform and tubular ACCs usually exhibit a more indolent course, whereas the solid subtype is associated with worse prognosis
  • ACC consists of two different cell types: inner luminal epithelial cells and outer myoepithelial cells
  • epithelial cells express c-kit, cox-2 and Bcl-2
  • myoepithelial cells express EGFR and MYB
  • a balanced translocation of the v-myb avian myeloblastosis viral oncogene homolog-nuclear factor I/B (MYB-NFIB) is considered to be a signature molecular event of ACC oncogenesis
  • As a transcription factor, MYB is known to modulate multiple genetic downstream targets involved in oncogenesis, such as cox-2, c-kit, Bcl-2 and BclX
  • Various signaling cascades are essential for cancer cells to survive and grow. The PI3K/Akt/mTOR pathway is one of them
  • This pathway regulates cell survival and growth and is upregulated in many cancers
  • Mutations in genes associated with DNA repair are frequently found in familial cancer syndromes, such as hereditary breast-ovarian cancer syndrome (HBOC), hereditary non-polyposis colorectal cancer (HNPCC, also called Lynch syndrome) and Li-Fraumeni syndrome [30, 31]. These mutations were also reported in non-hereditary cancers
  • 70% of ACC samples (58 of 84) were found to have genetic alterations in the MYB/MYC pathway, indicating that changes in this pathway are crucial in ACC pathogenesis
  • The second most frequently mutated pathway was involved in chromatin remodeling (epigenetic modification), a pathway that includes multiple histone related proteins, and was altered in 44% of samples
  • C-kit
  • VEGF, iNOS and NF-κB were noted to be highly expressed in ACC cells as compared to normal salivary gland cells
  • members of the SOX family, such as SOX 4 and SOX10, are overexpressed in ACC
  • FABP7 (Fatty acid binding protein 7) and AQP1 (Aquaporin 1) tend to be overexpressed in ACC cell lines
  • considerable variability in HER2 overexpression ranging from 0–58% in patients with ACC
  • the study with cetuximab and concurrent chemoradiation or chemotherapy showed the highest ORR (total 43%, 9.5% CR and 33% PR), but this regimen was only given to the EGFR positive patients
  • Cancer immunotherapy can be classified into 3 major groups. Active immunization using anti-tumor vaccines to induce and recruit T cells, passive immunization based on monoclonal antibodies, and adoptive cell transfer to expand tumor-reactive autologous T cells ex vivo and then reintroduce these cells into the same individual
  • LAK cells showed cytotoxicity against ACC cells
  • cytokine-induced cell apoptosis and the cytotoxic effect of the LAK cells contributed to tumor regression
  • molecular finding of the MYB-NFIB fusion gene has the greatest potential to target what appears to be a fundamental event in disease pathogenesis
  • Nathan Goodyear on 03 Oct 18
     
    good review of adenoid cystic carcinoma
1 - 18 of 18
Showing 20▼ items per page